Literature DB >> 1947828

Transperineal ultrasound-guided implantation of the prostate: morbidity and complications.

J C Blasko1, H Ragde, P D Grimm.   

Abstract

Two hundred and seventy four patients with early carcinoma of the prostate were treated by ultrasound-guided transperineal I-125 implantation. One hundred and ninety six received implant alone, and 78 were treated with combined external beam and I-125 implantation. Operative, early and late complications were reviewed with a median follow-up time of 40 months (minimum 13, maximum 64 months). Operative complications were negligible. Early morbidity (less than 12 months post implant) was noted in 10-15% of patients and consisted of self-limited irritative uropathy or obstruction. Late complications (more than 12 months post implant) were noted in 13%. Seven percent of patients had some combination of permanent sequelae of treatment: 14 patients had some degree of incontinence, 17 had irritative uropathy symptoms, and 7 had proctitis, 5 of whom resolved spontaneously. Most complications were mild to moderate with a notable absence of severe problems. Urinary morbidity was strongly related to prior or post-implant transurethral resection of the prostate (TURP) (24% with TURP, 3% without). Transperineal implantation in our experience is associated with an acceptable acute and chronic complication rate.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1947828

Source DB:  PubMed          Journal:  Scand J Urol Nephrol Suppl        ISSN: 0300-8886


  16 in total

1.  Acute urinary morbidity following I-125 prostate brachytherapy.

Authors:  Toshio Ohashi; Atsunori Yorozu; Kazuhito Toya; Shiro Saito; Tetsuo Momma
Journal:  Int J Clin Oncol       Date:  2005-08       Impact factor: 3.402

Review 2.  Recent developments and best practice in brachytherapy treatment planning.

Authors:  C D Lee
Journal:  Br J Radiol       Date:  2014-06-02       Impact factor: 3.039

3.  Can high-dose-rate brachytherapy prevent the major genitourinary complication better than external beam radiation alone for patients with previous transurethral resection of prostate?

Authors:  Hao Lun Luo; Fu Min Fang; Chih Hsiung Kang; Yao Chi Chuang; Po Hui Chiang
Journal:  Int Urol Nephrol       Date:  2012-09-13       Impact factor: 2.370

4.  Severe genitourinary toxicity following radiation therapy for prostate cancer--how long does it last?

Authors:  Sung Kim; Dirk F Moore; Weichung Shih; Yong Lin; Hui Li; Yu-Hsuan Shao; Shunhua Shen; Grace L Lu-Yao
Journal:  J Urol       Date:  2012-11-16       Impact factor: 7.450

5.  Modern brachytherapy for localized prostate cancers: the northwest hospital (Seattle) experience.

Authors:  L J Korb; M K Brawer
Journal:  Rev Urol       Date:  2001

6.  Advances in brachytherapy.

Authors:  Peter Grimm; John Sylvester
Journal:  Rev Urol       Date:  2004

7.  Needle position during (125)I seed implantation: accurately recognized by sagittal transrectal ultrasonography [corrected].

Authors:  Hiromichi Ishiyama; Shouko Kotani; Takefumi Satoh; Mineko Uemae; Shiro Baba; Kazushige Hayakawa
Journal:  Radiat Med       Date:  2008-10-31

Review 8.  Alternative therapies for localized prostate cancer.

Authors:  Harrie P Beerlage
Journal:  Curr Urol Rep       Date:  2003-06       Impact factor: 2.862

9.  Prospective multi-center dosimetry study of low-dose Iodine-125 prostate brachytherapy performed after transurethral resection.

Authors:  Carl Salembier; Alex Rijnders; Ann Henry; Peter Niehoff; Frank André Siebert; Peter Hoskin
Journal:  J Contemp Brachytherapy       Date:  2013-06-28

10.  Comparison between preoperative and real-time intraoperative planning ¹²⁵I permanent prostate brachytherapy: long-term clinical biochemical outcome.

Authors:  Haim Matzkin; Juza Chen; Larissa German; Nicola J Mabjeesh
Journal:  Radiat Oncol       Date:  2013-12-17       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.